It depends on what CCFA means.
There isn't a whole lot of evidence/ research on long-term medication use but some of the older studies conclude that there may not be much benefit of ASAs in patients who have long-term clinical remission ("long-term" measured as 2-3 years for most studies).
Generally, patients with less than 2-3 years of clinical remission are thought to be at risk of relapse and should continue with meds. And, patients with long-term remission are thought to be at low risk for relapse and these patients will relapse with or without medication.
For other medications, there's even less evidence for a variety of reasons (lack of studies, novelty of medication, etc.) and it can be difficult to determine whether continued medication leads to improved outcomes or not. For instance, a recent long-term study of Imuran/ 6-MP use found that almost all patients had discontinued the medication by the 8-year mark, but, if I remember correctly, that study didn't follow remission/ relapse.
I think it's also wise to consider the CCFA's audience (and, probably, funding, but that's a discussion for another thread). The attached document is written for a generalist audience, one that might be new to IBD, one that probably isn't going to immerse itself in medical research right away, so rather than try to juggle everything, it's just easier to issue a blanket recommendation.